IMVT-1402 difficult-to-treat RA registrational program update
IMVT-1402 difficult-to-treat RA registrational program update, expected in the second half of 2026 (no exact date yet). A company milestone for Immunovant (IMVT-1402 for difficult-to-treat rheumatoid arthritis): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
- Company
- Immunovant, Inc. IMVT
- Drug
- IMVT-1402
- For
- difficult-to-treat rheumatoid arthritis
- Stage
- potentially registrational · a study designed to support approval
- When
- H2 2026 · the company gave a window, not a day; the calendar never invents one
- Source note
- Fiscal Q1 2027 results PR (Aug 6, 2026). The CLE PoC topline (2H26) is already tracked; this is the separate D2T RA program update guided for the same window.
- Checked
- Checked by a person when it was added
- Source: immunovant.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- IMVT headlines on this site
Immunovant expects to report results from its Phase 2 study of IMVT-1402 (anti-FcRn) for Cutaneous lupus erythematosus in the second half of 2026 (no exact date yet). Phase 2 is the stage that tests whether the drug actually works.
More details
- Entry
- IMVT-1402 proof-of-concept topline in cutaneous lupus (CLE) · Clinical trial results (readout / topline data)
- Drug
- IMVT-1402 (anti-FcRn)
- For
- Cutaneous lupus erythematosus
- Stage
- Phase 2 · the stage that tests whether the drug actually works
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Fiscal Q1 update (Aug 6, 2026): topline proof-of-concept data expected in second half of calendar year 2026; D2T RA registrational program update also expected 2H 2026.
- Checked
- Checked by a person when it was added
- Verify it
- Source: immunovant.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- IMVT headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Immunovant expects to report results from its Potentially registrational study of IMVT-1402 (anti-FcRn) for Graves' disease during 2027 (no exact date yet). Potentially registrational is a study designed to support approval.
More details
- Entry
- IMVT-1402 registrational topline in Graves' disease · Clinical trial results (readout / topline data)
- Drug
- IMVT-1402 (anti-FcRn)
- For
- Graves' disease
- Stage
- Potentially registrational · a study designed to support approval
- When
- 2027 · the company gave a window, not a day
- Source note
- Company guidance (Aug 6, 2026): topline data from the potentially registrational Graves' trial expected in calendar year 2027 (year-level precision only).
- Checked
- Checked by a person when it was added
- Verify it
- Source: immunovant.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- IMVT headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page